Chronic kidney disease (CKD) is a major health care problem, affecting more than 35% of the elderly population worldwide. New interventions to slow or prevent disease progression are urgently needed. Beneficial effects of mesenchymal stem cells (MSC) have been described, however it is unclear whether the MSCs themselves or their secretome is required. We hypothesized that MSC-derived conditioned medium (CM) reduces progression of CKD and studied functional and structural effects in a rat model of established CKD. CKD was induced by 5/6 nephrectomy (SNX) combined with L-NNA and 6% NaCl diet in Lewis rats. Six weeks after SNX, CKD rats received either 50 μg CM or 50 μg non-CM (NCM) twice daily intravenously for four consecutive days. Six weeks after treatment CM administration was functionally effective: glomerular filtration rate (inulin clearance) and effective renal plasma flow (PAH clearance) were significantly higher in CM vs. NCM-treatment. Systolic blood pressure was lower in CM compared to NCM. Proteinuria tended to be lower after CM. Tubular and glomerular damage were reduced and more glomerular endothelial cells were found after CM. DNA damage repair was increased after CM. MSC-CM derived exosomes, tested in the same experimental setting, showed no protective effect on the kidney. In a rat model of established CKD, we demonstrated that administration of MSC-CM has a long-lasting therapeutic rescue function shown by decreased progression of CKD and reduced hypertension and glomerular injury.
References
[1]
Vinhas J, Gardete-Correia L, Boavida JM, Raposo JF, Mesquita A, et al. (2011) Prevalence of Chronic Kidney Disease and Associated Risk Factors, and Risk of End-Stage Renal Disease: Data from the PREVADIAB Study. Nephron Clin Pract 119: c35–c40.
[2]
Zhang QL, Rothenbacher D (2008) Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8: 117.
[3]
Levin A, Stevens PE (2011) Early detection of CKD: the benefits, limitations and effects on prognosis. Nat Rev Nephrol 7: 446–457.
[4]
McDonald SP, Tong B (2011) Morbidity burden of end-stage kidney disease in Australia: Hospital separation rates among people receiving kidney replacement therapy. Nephrology (Carlton ) 16: 758–766.
[5]
Imai N, Kaur T, Rosenberg ME, Gupta S (2009) Cellular therapy of kidney diseases. Semin Dial 22: 629–635.
Humphreys BD, Bonventre JV (2008) Mesenchymal stem cells in acute kidney injury. Annu Rev Med 59: 311–325.
[8]
Kunter U, Rong S, Boor P, Eitner F, Muller-Newen G, et al. (2007) Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol 18: 1754–1764.
[9]
Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, et al. (2007) Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110: 1362–1369.
[10]
Foudah D, Redaelli S, Donzelli E, Bentivegna A, Miloso M, et al. (2009) Monitoring the genomic stability of in vitro cultured rat bone-marrow-derived mesenchymal stem cells. Chromosome Res 17: 1025–1039.
[11]
Jeong JO, Han JW, Kim JM, Cho HJ, Park C, et al. (2011) Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res 108: 1340–1347.
[12]
Bi B, Schmitt R, Israilova M, Nishio H, Cantley LG (2007) Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 18: 2486–2496.
[13]
Gheisari Y, Ahmadbeigi N, Naderi M, Nassiri SM, Nadri S, et al. (2011) Stem cell-conditioned medium does not protect against kidney failure. Cell Biol Int 35: 209–213.
[14]
Imberti B, Morigi M, Tomasoni S, Rota C, Corna D, et al. (2007) Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol 18: 2921–2928.
[15]
Togel F, Weiss K, Yang Y, Hu Z, Zhang P, et al. (2007) Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 292: F1626–F1635.
[16]
Togel F, Zhang P, Hu Z, Westenfelder C (2009) VEGF is a mediator of the renoprotective effects of multipotent marrow stromal cells in acute kidney injury. J Cell Mol Med 13: 2109–2114.
[17]
Zarjou A, Kim J, Traylor AM, Sanders PW, Balla J, et al. (2011) Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1. Am J Physiol Renal Physiol 300: F254–F262.
[18]
Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, et al. (2009) Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 20: 1053–1067.
[19]
Gatti S, Bruno S, Deregibus MC, Sordi A, Cantaluppi V, et al. (2011) Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 26: 1474–1483.
[20]
Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L (2010) Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 78: 838–848.
[21]
Lai RC, Arslan F, Lee MM, Sze NS, Choo A, et al. (2010) Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 4: 214–222.
[22]
Timmers L, Lim SK, Hoefer IE, Arslan F, Lai RC, et al. (2011) Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 6: 206–214.
[23]
MacPhail SH, Banath JP, Yu Y, Chu E, Olive PL (2003) Cell cycle-dependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not X-irradiated G1-phase cells. Radiat Res 159: 759–767.
[24]
MacPhail SH, Banath JP, Yu TY, Chu EH, Lambur H, et al. (2003) Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol 79: 351–358.
[25]
Caldas HC, Fernandes IM, Gerbi F, Souza AC, Baptista MA, et al. (2008) Effect of whole bone marrow cell infusion in the progression of experimental chronic renal failure. Transplant Proc 40: 853–855.
[26]
Cavaglieri RC, Martini D, Sogayar MC, Noronha IL (2009) Mesenchymal stem cells delivered at the subcapsule of the kidney ameliorate renal disease in the rat remnant kidney model. Transplant Proc 41: 947–951.
[27]
Lee SR, Lee SH, Moon JY, Park JY, Lee D, et al. (2010) Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney model. Ren Fail 32: 840–848.
[28]
Villanueva S, Ewertz E, Carrion F, Tapia A, Vergara C, et al. (2011) Mesenchymal stem cell injection ameliorates chronic renal failure in a rat model. Clin Sci (Lond) 121: 489–499.
[29]
Semedo P, Correa-Costa M, Antonio CM, Maria Avancini Costa MD, Antonia dos RM, et al. (2009) Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cells 27: 3063–3073.
[30]
La Manna G, Bianchi F, Cappuccilli M, Cenacchi G, Tarantino L, et al. (2010) Mesenchymal stem cells in renal function recovery after acute kidney injury. Use of a differentiating agent in a rat model. Cell Transplant.
[31]
Fleck C, Appenroth D, Jonas P, Koch M, Kundt G, et al. (2006) Suitability of 5/6 nephrectomy (5/6NX) for the induction of interstitial renal fibrosis in rats–influence of sex, strain, and surgical procedure. Exp Toxicol Pathol 57: 195–205.
[32]
Griffin KA, Picken MM, Churchill M, Churchill P, Bidani AK (2000) Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat. J Am Soc Nephrol 11: 497–506.
[33]
Darling IM, Morris ME (1991) Evaluation of “true” creatinine clearance in rats reveals extensive renal secretion. Pharm Res 8: 1318–1322.
[34]
Hostetter TH, Meyer TW (2004) The development of clearance methods for measurement of glomerular filtration and tubular reabsorption. Am J Physiol Renal Physiol 287: F868–F870.
[35]
van Koppen A, Joles JA, Bongartz LG, van den Brandt J, Reichardt HM, et al. (2012) Healthy bone marrow cells reduce progression of kidney failure better than CKD bone marrow cells in rats with established chronic kidney disease. Cell Transplant in press.
[36]
Rookmaaker MB, Smits AM, Tolboom H, Van’t Woud K, Martens AC, et al. (2003) Bone-marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis. Am J Pathol 163: 553–562.
[37]
Mizutani N, Sakurai T, Shibata T, Uchida K, Fujita J, et al. (2007) Dose-dependent differential regulation of cytokine secretion from macrophages by fractalkine. J Immunol 179: 7478–7487.
[38]
Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16: 27–55.
[39]
Katsha AM, Ohkouchi S, Xin H, Kanehira M, Sun R, et al. (2011) Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther 19: 196–203.
[40]
Yew TL, Hung YT, Li HY, Chen HW, Chen LL, et al. (2011) Enhancement of Wound Healing by Human Multipotent Stromal Cell Conditioned Medium: The Paracrine Factors and p38 MAPK Activation. Cell Transplant 20: 693–706.
[41]
Sze SK, de Kleijn DP, Lai RC, Khia Way TE, Zhao H, et al. (2007) Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells. Mol Cell Proteomics 6: 1680–1689.
[42]
Brunswig-Spickenheier B, Boche J, Westenfelder C, Peimann F, Gruber AD, et al. (2010) Limited immune-modulating activity of porcine mesenchymal stromal cells abolishes their protective efficacy in acute kidney injury. Stem Cells Dev 19: 719–729.
[43]
Tornig J, Amann K, Ritz E, Nichols C, Zeier M, et al. (1996) Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7: 667–675.
[44]
Lian Q, Lye E, Suan YK, Khia Way TE, Salto-Tellez M, et al. (2007) Derivation of clinically compliant MSCs from CD105+. Stem Cells 25: 425–436.
[45]
Koeners MP, Racasan S, Koomans HA, Joles JA, Braam B (2007) Nitric oxide, superoxide and renal blood flow autoregulation in SHR after perinatal L-arginine and antioxidants. Acta Physiol (Oxf) 190: 329–338.
[46]
Bongartz LG, Braam B, Verhaar MC, Cramer MJ, Goldschmeding R, et al. (2010) The nitric oxide donor molsidomine rescues cardiac function in rats with chronic kidney disease and cardiac dysfunction. Am J Physiol Heart Circ Physiol 299: H2037–H2045.
[47]
Attia DM, Verhagen AM, Stroes ES, van Faassen EE, Grone HJ, et al. (2001) Vitamin E alleviates renal injury, but not hypertension, during chronic nitric oxide synthase inhibition in rats. J Am Soc Nephrol 12: 2585–2593.
[48]
Kunter U, Rong S, Djuric Z, Boor P, Muller-Newen G, et al. (2006) Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 17: 2202–2212.
[49]
Niemisto A, Dunmire V, Yli-Harja O, Zhang W, Shmulevich I (2005) Robust quantification of in vitro angiogenesis through image analysis. IEEE Trans Med Imaging 24: 549–553.
